Study to Evaluate the Efficacy, Safety and Tolerability of N1539

PHASE2CompletedINTERVENTIONAL
Enrollment

486

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Hysterectomy
Interventions
DRUG

N1539

5 mg IV once per day

DRUG

N1539

7.5 mg IV once per day

DRUG

N1539

15 mg IV once per day

DRUG

N1539

30 mg IV once per day

DRUG

placebo

IV placebo once per day

DRUG

Morphine

morphine 10-15 mg IV once per day

DRUG

N1539

60 mg IV once per day

Trial Locations (12)

11000

Belgrade

21000

Novi Sad

34000

Kragujevac

0159

Tbilisi

0186

Tbilisi

15-276

Bialystok

80-402

Gdansk

94-029

Lodz

20-081

Lublin

60-535

Poznan

41-703

Ruda Śląska

70-111

Szczecin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY